MedTrace Logo

A Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP)

NCT03988335 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2022-04-05

Study results available
· View outcomes & findings →

Summary

A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects with Palmoplantar Pustulosis

Conditions

  • Palmoplantar Pustulosis

Interventions

DRUG

RIST4721

RIST4721 oral solution

DRUG

Placebo

Placebo oral solution

Sponsors & Collaborators

  • Aristea Therapeutics, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-13
Primary Completion
2019-11-05
Completion
2019-11-19

Countries

  • Canada
  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03988335 on ClinicalTrials.gov